PRG S&T
CompanySouth Korea
PRG S&T develops one asset, in phase 2 (progerinin in adult progeria). Mostly small molecule acting on LMNA, proteostasis and cellular senescence; based in South Korea.
- 1
- Asset
- Furthest stage
- Phase 2
- 0
- Trials
- 0
- Signals
Pipeline
1Inhibits progerin binding to lamin A.
Phase 2, Small molecule, LMNA, Proteostasis, adult progeria, aging
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms4
- Signals1
- Similar companies6